Although a significant portion of the increase in prostate cancer survival in the general population can be attributed to the rise in diagnoses of tumors with favorable prognoses resulting from the widespread use of the prostate-specific antigen (PSA) tests, flaws in population studies may have influenced the observed data among various countries. This evidence concerns the gene KLK3 and Familial prostate cancer.